Journal issues > Issue SPECIAL, April 2022 > Management of myelofibrosis: Novel approaches and recent evolutions

Management of myelofibrosis: Novel approaches and recent evolutions

Myelofibrosis (MF) is a chronic malignancy characterised by marrow fibrosis and myeloproliferation caused by a constitutive activation of the Janus-activated kinase (JAK) transcription signalling pathway. This constitutive activation is usually the result of mutations in the driver genes JAK2, myeloproliferative leukaemia virus (MPL) or calreticulin (CALR).¹ The most important clinical manifestation of MF consists of splenomegaly, in addition to hepatomegaly, cytopenia (mainly anaemia), and constitutional symptoms.² MF significantly decreases the life expectancy of patients with a median survival of less than six years.³ During the 37^th general annual meeting of the Belgian Haematology Society, professor Jean-Jacques Kiladjian (Saint Louis Hospital, Paris, France) discussed the contemporary management of this disease.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top